Other examples include prevention of metastases through targeting of SRC expression in orthotopic mouse models of human pancreatic adenocarcinoma54 or dual pharmacological inhibition of MET and VEGFR2 (ref.55) in various tumour models and tumour cell lines, or transgenic mice in which mammary tumour development and metastasis are driven by the expression of HER2 (ref.56) or E545K-mutant PIK3CA57. This evidence concerns the gene ERBB2 and neoplasm.